A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis	CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic progressive multiple sclerosis, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder, relapsing-remitting multiple sclerosis	Active, not recruiting	Phase 1	2026-08-13		NCT07667322

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Hoffmann-La Roche	280

12 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Centro de Investigacion Medico Biologico y Terapia Avanzada, S.C.	Guadalajara	Mexico	2
Centro de Pesquisas Clinicas	São Paulo	Brazil	8
Hope Neurology	Knoxville	United States	7
Inovacion y Desarrollo en ciencias de la salud	Mexico City	Mexico	2
Instituto de Neurologia de Curitiba	Curitiba	Brazil	15
John Hopkins University School of Medicine	Baltimore	United States	6
Morriston Hospital	Swansea	United Kingdom	10
Neurology Associates, PA	Maitland	United States	4
Nottingham University Hospitals NHS Trust	Nottingham	United Kingdom	11
Profound Research, LLC	Carlsbad	United States	4
Shepherd Center Inc.	Atlanta	United States	1
University of South Florida	Tampa	United States	73